{"transactions":[{"id":719813,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:20.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294859","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294859/ownership.xml","form_type":"4"}},{"id":731717,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-06-18T21:00:23.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":39453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":39453,"derivative":{"exercise_price":15,"expiration_date":"2036-06-16","underlying":"Ordinary Shares","underlying_shares":39453},"source":{"system":"sec-edgar","filing":"0001534002-26-000002","document":"form4-06182026_050614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000153400226000002/form4-06182026_050614.xml","form_type":"4"}},{"id":1096708,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:07.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093468/ownership.xml","form_type":"4"}},{"id":1101515,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-06-25T21:45:15.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":42833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":42833,"derivative":{"exercise_price":7.37,"expiration_date":"2035-06-22","underlying":"Ordinary Shares","underlying_shares":42833},"source":{"system":"sec-edgar","filing":"0001415889-25-018218","document":"form4-06252025_050611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000141588925018218/form4-06252025_050611.xml","form_type":"4"}},{"id":1280269,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T15:45:31.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015322/ownership.xml","form_type":"4"}},{"id":1280268,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T15:45:31.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":36506,"price":3.65,"value":133246.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000950170-25-015322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015322/ownership.xml","form_type":"4"}},{"id":1420626,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2024-08-28T20:37:31.000Z","date":"2024-08-26","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of August 26, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":13.53,"expiration_date":"2034-08-25","underlying":"Ordinary Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-24-022457","document":"form4-08282024_080826.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000141588924022457/form4-08282024_080826.xml","form_type":"4"}},{"id":1461370,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:09.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081606","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081606/ownership.xml","form_type":"4"}},{"id":1528121,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-03T08:47:11.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":23458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":23458,"derivative":{"exercise_price":3.795,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":23458},"source":{"system":"sec-edgar","filing":"0001479290-24-000089","document":"wk-form4_1714740423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000089/wk-form4_1714740423.xml","form_type":"4"}},{"id":1528120,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-03T08:47:11.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":51506,"source":{"system":"sec-edgar","filing":"0001479290-24-000089","document":"wk-form4_1714740423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000089/wk-form4_1714740423.xml","form_type":"4"}},{"id":1840350,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:06.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023348/ownership.xml","form_type":"4"}},{"id":1902649,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-05-05T17:14:24.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":5915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Russell's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":5915,"derivative":{"exercise_price":33.61,"expiration_date":"2033-05-02","underlying":"Common Stock","underlying_shares":5915},"source":{"system":"sec-edgar","filing":"0001479290-23-000060","document":"wf-form4_168332125216237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000060/wf-form4_168332125216237.xml","form_type":"4"}},{"id":1902648,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T17:14:24.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":3534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Russell's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":36506,"source":{"system":"sec-edgar","filing":"0001479290-23-000060","document":"wf-form4_168332125216237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000060/wf-form4_168332125216237.xml","form_type":"4"}},{"id":2148454,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-03T22:43:28.000Z","date":"2022-09-29","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer.  The RSU's will vest on September 29, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer.  The RSU's will vest on September 29, 2023."}],"balance_after":5000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-051961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122051961/doc4.xml","form_type":"4"}},{"id":2177780,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-22T10:00:38.000Z","date":"2022-08-18","kind":"exercise","acquired":false,"shares":1984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested on July 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1984},"source":{"system":"sec-edgar","filing":"0001209191-22-046966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122046966/doc4.xml","form_type":"4"}},{"id":2177779,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T10:00:38.000Z","date":"2022-08-18","kind":"exercise","acquired":true,"shares":1984,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022."}],"balance_after":5792,"source":{"system":"sec-edgar","filing":"0001209191-22-046966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122046966/doc4.xml","form_type":"4"}},{"id":2213197,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:16:02.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018685","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018685/ownership.xml","form_type":"4"}},{"id":2271988,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-13T18:17:26.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":10756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Russell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy."}],"balance_after":10756,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":10756},"source":{"system":"sec-edgar","filing":"0001479290-22-000071","document":"wf-form4a_165248019122400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000071/wf-form4a_165248019122400.xml","form_type":"4/A","original_submission_date":"2022-05-06"}},{"id":2279274,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-06T18:18:08.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":11343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":11343,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":11343},"source":{"system":"sec-edgar","filing":"0001479290-22-000059","document":"wf-form4_165187546396953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000059/wf-form4_165187546396953.xml","form_type":"4"}},{"id":2279273,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-06T18:18:08.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":6059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":32972,"source":{"system":"sec-edgar","filing":"0001479290-22-000059","document":"wf-form4_165187546396953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000059/wf-form4_165187546396953.xml","form_type":"4"}},{"id":2471563,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T20:17:19.000Z","date":"2021-12-13","kind":"purchase","acquired":true,"shares":6400,"price":15.7408,"value":100741.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $15.65 to $15.81. Mr. Russell undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":26913,"source":{"system":"sec-edgar","filing":"0001479290-21-000173","document":"wf-form4_163961742195547.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000173/wf-form4_163961742195547.xml","form_type":"4"}},{"id":2606320,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-08-13T01:38:00.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":96864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each RSU represented a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested on June 18, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested on June 18, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each RSU represented a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":96864},"source":{"system":"sec-edgar","filing":"0001387131-21-008440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008440/ownership.xml","form_type":"4"}},{"id":2606319,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-13T01:38:00.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":96864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."}],"balance_after":190364,"source":{"system":"sec-edgar","filing":"0001387131-21-008440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008440/ownership.xml","form_type":"4"}},{"id":2646989,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-07-02T22:07:17.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":99174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022."}],"balance_after":99174,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":99174},"source":{"system":"sec-edgar","filing":"0001387131-21-007133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007133/ownership.xml","form_type":"4"}},{"id":2648860,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T22:24:23.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":2.86,"expiration_date":"2031-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-21-015886","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221015886/ownership.xml","form_type":"4"}},{"id":2650856,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T22:58:12.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":24720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":2.2,"expiration_date":"2021-06-30","underlying":"Common Shares","underlying_shares":24720},"source":{"system":"sec-edgar","filing":"0001493152-21-015786","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221015786/ownership.xml","form_type":"4"}},{"id":2650855,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2021-06-30T22:58:12.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":4720,"price":2.97,"value":14018.4,"ownership":{"direct":true},"balance_after":87500,"source":{"system":"sec-edgar","filing":"0001493152-21-015786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221015786/ownership.xml","form_type":"4"}},{"id":2650854,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2021-06-30T22:58:12.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":24720,"price":2.2,"value":54384.0,"ownership":{"direct":true},"balance_after":92220,"source":{"system":"sec-edgar","filing":"0001493152-21-015786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221015786/ownership.xml","form_type":"4"}},{"id":2723088,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-05-07T19:12:37.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":7551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":7551,"derivative":{"exercise_price":27.91,"expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":7551},"source":{"system":"sec-edgar","filing":"0001479290-21-000114","document":"wf-form4_162042912990502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000114/wf-form4_162042912990502.xml","form_type":"4"}},{"id":2723087,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-07T19:12:37.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":4013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":20513,"source":{"system":"sec-edgar","filing":"0001479290-21-000114","document":"wf-form4_162042912990502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000114/wf-form4_162042912990502.xml","form_type":"4"}},{"id":2979438,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-11-16T21:12:15.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":51789,"price":0.1287,"value":6665.2443,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.125 to $0.131, inclusive. Mr. Russell will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950138-20-000467","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013820000467/edgar.xml","form_type":"4"}},{"id":3093735,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T21:01:59.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable on July 1, 2021, based upon continued service on the board of directors."}],"balance_after":40000,"derivative":{"exercise_price":0.8263,"expiration_date":"2030-07-01","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-20-012533","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315220012533/ownership.xml","form_type":"4"}},{"id":3104964,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:10:36.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":96864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021."}],"balance_after":96864,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":96864},"source":{"system":"sec-edgar","filing":"0001387131-20-005820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120005820/ownership.xml","form_type":"4"}},{"id":3146853,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-05-15T20:48:36.000Z","date":"2020-05-13","kind":"tax_withholding","acquired":false,"shares":12042,"price":2.96,"value":35644.32,"ownership":{"direct":true},"balance_after":51789,"source":{"system":"sec-edgar","filing":"0000950138-20-000265","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013820000265/edgar.xml","form_type":"4"}},{"id":3147217,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-05-15T18:34:50.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":19.4,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001479290-20-000065","document":"wf-form4_158958207301515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000065/wf-form4_158958207301515.xml","form_type":"4"}},{"id":3147216,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T18:34:50.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":16500,"source":{"system":"sec-edgar","filing":"0001479290-20-000065","document":"wf-form4_158958207301515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000065/wf-form4_158958207301515.xml","form_type":"4"}},{"id":3429769,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-26T21:14:34.000Z","date":"2019-08-23","kind":"purchase","acquired":true,"shares":10000,"price":2.77,"value":27700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4."}],"balance_after":93500,"source":{"system":"sec-edgar","filing":"0001387131-19-006399","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713119006399/ownership.xml","form_type":"4"}},{"id":3438355,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-15T20:33:21.000Z","date":"2019-08-15","kind":"purchase","acquired":true,"shares":10000,"price":2.99,"value":29900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.00, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (2) to this Form 4."}],"balance_after":83500,"source":{"system":"sec-edgar","filing":"0001387131-19-006191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713119006191/ownership.xml","form_type":"4"}},{"id":3438354,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-15T20:33:21.000Z","date":"2019-08-14","kind":"purchase","acquired":true,"shares":25000,"price":2.76,"value":69000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.73 to $2.77, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4."}],"balance_after":73500,"source":{"system":"sec-edgar","filing":"0001387131-19-006191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713119006191/ownership.xml","form_type":"4"}},{"id":3469419,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-04T01:09:44.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable on June 30, 2020, based upon continued service on the board of directors."}],"balance_after":40000,"derivative":{"exercise_price":1.03,"expiration_date":"2029-06-30","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-041304","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919119041304/doc4.xml","form_type":"4"}},{"id":3480831,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-06-24T23:03:28.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":75000,"derivative":{"exercise_price":2.64,"exercise_date":"2020-06-20","expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001387131-19-004588","document":"russell-form4_062019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713119004588/russell-form4_062019.xml","form_type":"4"}},{"id":3520174,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-17T11:08:46.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":26759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":63831,"source":{"system":"sec-edgar","filing":"0000950138-19-000314","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013819000314/edgar.xml","form_type":"4"}},{"id":3520173,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-17T11:08:46.000Z","date":"2019-05-15","kind":"tax_withholding","acquired":false,"shares":11764,"price":15.21,"value":178930.44,"ownership":{"direct":true},"balance_after":37072,"source":{"system":"sec-edgar","filing":"0000950138-19-000314","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013819000314/edgar.xml","form_type":"4"}},{"id":3531507,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-05-10T21:09:09.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":9000,"derivative":{"exercise_price":12.82,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001479290-19-000060","document":"wf-form4_155753693463342.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000060/wf-form4_155753693463342.xml","form_type":"4"}},{"id":3531506,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:09:09.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001479290-19-000060","document":"wf-form4_155753693463342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000060/wf-form4_155753693463342.xml","form_type":"4"}},{"id":3873832,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-07-05T21:02:32.000Z","date":"2018-07-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":6.35,"exercise_date":"2019-07-02","expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001387131-18-003030","document":"russell-form4_070218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713118003030/russell-form4_070218.xml","form_type":"4"}},{"id":3877048,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Shares","published_at":"2018-07-03T22:34:54.000Z","date":"2018-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable on June 30, 2019, based upon continued service on the board of directors."}],"balance_after":40000,"derivative":{"exercise_price":2.06,"expiration_date":"2023-06-30","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-041308","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919118041308/doc4.xml","form_type":"4"}},{"id":3925357,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-18T20:21:15.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":26141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":48836,"source":{"system":"sec-edgar","filing":"0000950138-18-000415","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013818000415/edgar.xml","form_type":"4"}},{"id":3937016,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-05-11T20:30:52.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":6000,"derivative":{"exercise_price":29.15,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001479290-18-000080","document":"wf-form4_152608499215478.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000080/wf-form4_152608499215478.xml","form_type":"4"}},{"id":3937015,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-11T20:30:52.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001479290-18-000080","document":"wf-form4_152608499215478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000080/wf-form4_152608499215478.xml","form_type":"4"}},{"id":4013766,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-03-05T21:34:54.000Z","date":"2018-03-01","kind":"tax_withholding","acquired":false,"shares":2576,"price":15.68,"value":40391.68,"ownership":{"direct":true},"balance_after":22695,"source":{"system":"sec-edgar","filing":"0000950138-18-000216","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013818000216/edgar.xml","form_type":"4"}},{"id":4193752,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-10-03T21:10:48.000Z","date":"2017-10-01","kind":"tax_withholding","acquired":false,"shares":476,"price":37.37,"value":17788.12,"ownership":{"direct":true},"balance_after":25271,"source":{"system":"sec-edgar","filing":"0000950138-17-000706","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013817000706/edgar.xml","form_type":"4"}},{"id":4266117,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Shares","published_at":"2017-07-05T23:52:06.000Z","date":"2017-07-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors."}],"balance_after":20000,"derivative":{"exercise_price":3.15,"expiration_date":"2022-06-30","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-043781","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919117043781/doc4.xml","form_type":"4"}},{"id":4274186,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-06-23T20:31:50.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":5.8,"exercise_date":"2018-06-21","expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001387131-17-003413","document":"russell-form4_062117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117003413/russell-form4_062117.xml","form_type":"4"}},{"id":4322691,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-12T19:44:54.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy."}],"balance_after":6000,"derivative":{"exercise_price":20.9,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-17-032202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117032202/doc4.xml","form_type":"4"}},{"id":4322690,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-12T19:44:54.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Mr. Russell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-17-032202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117032202/doc4.xml","form_type":"4"}},{"id":4402547,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-03-03T23:44:41.000Z","date":"2017-03-01","kind":"tax_withholding","acquired":false,"shares":2286,"price":51.55,"value":117843.3,"ownership":{"direct":true},"balance_after":25747,"source":{"system":"sec-edgar","filing":"0000950138-17-000263","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013817000263/edgar.xml","form_type":"4"}},{"id":4402546,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-03-03T23:44:41.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":5723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":28033,"source":{"system":"sec-edgar","filing":"0000950138-17-000263","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013817000263/edgar.xml","form_type":"4"}},{"id":4513936,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-12-23T00:13:12.000Z","date":"2016-12-21","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":5.68,"exercise_date":"2017-12-21","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001387131-16-008710","document":"russell-form4_12212016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713116008710/russell-form4_12212016.xml","form_type":"4"}},{"id":4585968,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2016-10-04T13:06:39.000Z","date":"2016-10-01","kind":"grant","acquired":true,"shares":1057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of October 1, 2017. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":22310,"source":{"system":"sec-edgar","filing":"0000950138-16-001375","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534002/000095013816001375/edgar.xml","form_type":"4"}}]}